MOLN

MOLECULAR PARTNERS AG

• TipRanks·5d ago

  Molecular Partners selects MP0730 as lead Radio-DARPin candidate

• TipRanks·09/25 16:30

  Molecular Partners’ MP0533 Trial Completion: What AML Data Could Mean for MOLN Investors

• TipRanks·09/04 20:15

  Clear Street transfers coverage on Molecular Partners, keeps Buy rating

• TipRanks·08/25 20:15

  Molecular Partners: Pipeline Momentum and Early Safety Data Support Unchanged $12 Price Target and Buy Rating

• Seeking Alpha·08/25 11:54

  Molecular Partners GAAP EPS of -CHF0.70

• TipRanks·08/25 10:27

  Molecular Partners Advances DLL3 Radio-DARPin MP0712 and Expands Alpha Therapy Pipeline on Solid H1 2026 Cash Base

• NASDAQ·08/25 10:18

  Molecular Partners Reports H1 2026 Results, Advances DLL3 Radiotherapy MP0712

• TipRanks·07/20 12:48

  Molecular Partners Starts Phase 2 TACTIC Trial of MP0317 in Front-Line Cholangiocarcinoma

• TipRanks·07/16 09:41

  Molecular Partners doses first patients in MP0317 combination study

• NASDAQ·07/16 07:38

  Molecular Partners Advanced Phase 2 Study Of MP0317 In Cholangiocarcinoma; Stock Up

• TipRanks·07/11 14:35

  LifeSci Capital Sticks to Their Buy Rating for Molecular Partners (MOLN)

• TipRanks·07/07 10:29

  Molecular Partners Advances Radio-DARPin Cancer Pipeline With MP0712 Trial and Upcoming MP0726 Imaging

• TipRanks·07/06 10:30

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Alnylam Pharma (ALNY), Molecular Partners (MOLN) and Exelixis (EXEL)

• NASDAQ·07/06 09:53

  Molecular Partners To Advance MP0726 For First Human Imaging In H2,2026; Provides MP0712 Update

• TipRanks·07/02 10:45

  Molecular Partners Reaffirmed at Buy as Analyst Cites MP0712 Progress and Keeps $12 Price Target Unchanged